SuperworthWest Pharmaceutical Services WST
- Market cap
- $27.6B
- PE
- 50.2×
- 10y median 45.8×
- Forward PE
- 42.2×
- 10y median 41.7×
- Price to sales
- 8.3×
- EV/EBIT
- 39.5×
- Revenue, 12 months
- $3.3B
- +12% on a year ago
- Net margin
- 17.0%
- Free cash flow yield
- 1.6%
West Pharmaceutical Services trades at 50.2× trailing earnings, pricier than 70% of the last ten years. Revenue was $3.3B over the last twelve months, up 12% on a year earlier with a 17% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $747.4M+9% | $732M+3% | $695.4M−3% | $702.1M−7% | $746.9M−0% | $748.8M+2% | $698M+0% | $766.5M+9% | $804.6M+8% | $805M+8% | $844.9M+21% | $872.3M+14% | |
| Cost of revenue | $459.1M+10% | $453.8M+2% | $465.2M+5% | $472.1M+2% | $482.2M+5% | $475.2M+5% | $466.1M+0% | $492.6M+4% | $510.3M+6% | $501.1M+6% | $548.5M+18% | $543.1M+10% |
| Gross profit | $288.3M+8% | $278.2M+6% | $230.2M−15% | $230M−21% | $264.7M−8% | $273.6M−2% | $231.9M+1% | $273.9M+19% | $294.3M+11% | $303.9M+11% | $296.4M+28% | $329.2M+20% |
| R&D | $16.4M+21% | $18.4M+16% | $17.6M+3% | $17.5M+6% | $15.5M−6% | $18.5M+1% | $16.3M−7% | $19.1M+9% | $17.1M+10% | $21.8M+18% | $15.8M−3% | $19.7M+3% |
| SG&A | $89M+34% | $90M+5% | $86.7M+1% | $83M−6% | $83.5M−6% | $85.3M−5% | $88M+2% | $95.9M+16% | $102.7M+23% | $107M+25% | $99.5M+13% | $117.6M+23% |
| $177.3M−5% | $160.9M+24% | $122.8M−21% | $126.2M−31% | $161.3M−9% | $159.6M−1% | $107M−13% | $153.7M+22% | $167.6M+4% | $156.6M−2% | $177.1M+66% | $179.1M+17% | |
| Interest expense | $2.9M+32% | $1.2M−29% | $1.6M−27% | $1.5M−44% | $700K−76% | −$800K | $400K−75% | $100K−93% | $200K−71% | −$200K−75% | $1.9M+375% | $2.6M+2500% |
| Pre-tax income | $187M+37% | $168.2M+31% | $127.4M−19% | $128.7M−30% | $164.5M−12% | $164.9M−2% | $110.5M−13% | $157M+22% | $171.9M+5% | $161.5M−2% | $180.1M+63% | $180.1M+15% |
| $29.4M+44% | $34.5M+19% | $16.4M−31% | $21.9M−37% | $32.4M+10% | $36.8M+7% | $24.1M+47% | $30.2M+38% | $34M+5% | $33.3M−10% | $44.7M+86% | $32.2M+7% | |
| Net income | $161.3M+34% | $137M+33% | $115.3M−18% | $111.3M−28% | $136M−16% | $130.1M−5% | $89.8M−22% | $131.8M+18% | $140M+3% | $132.1M+2% | $138.8M+55% | $154M+17% |
| $2.14+35% | $1.83+35% | $1.55−16% | $1.51−27% | $1.85−14% | $1.77−3% | $1.23−21% | $1.82+21% | $1.92+4% | $1.82+3% | $1.92+56% | $2.15+18% | |
| 75.3M−1% | 74.7M−1% | 74.3M−2% | 73.7M−2% | 73.4M−3% | 73.4M−2% | 73M−2% | 72.5M−2% | 72.6M−1% | 72.7M−1% | 72.4M−1% | 71.3M−2% |
EPS, diluted: 16 periods, Q4 FY09 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 17 periods, Q4 FY09 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Estimates
Next earnings report: .
| Quarter | Revenue | Range | EPS | Range | Analysts |
|---|---|---|---|---|---|
| Q3 FY26 | $827.1M | $821.9M to $830.5M | $2.20 | $2.16 to $2.23 | 10 |
| Q4 FY26 | $828.1M | $822.6M to $834.7M | $2.27 | $2.25 to $2.29 | 8 |
| Q1 FY27 | $863.3M | $856.2M to $874.3M | $2.29 | $2.26 to $2.32 | 3 |
| Q2 FY27 | $899.2M | $891.8M to $910.6M | $2.51 | $2.48 to $2.55 | 4 |
| Q3 FY27 | $896.3M | $888.9M to $907.6M | $2.53 | $2.50 to $2.57 | 3 |
| Q4 FY27 | $903.3M | $895.9M to $914.8M | $2.63 | $2.60 to $2.67 | 4 |
| Q1 FY28 | $891.4M | $884.1M to $902.7M | $2.51 | $2.48 to $2.55 | 4 |
| Q2 FY28 | $930.6M | $923M to $942.4M | $2.71 | $2.68 to $2.75 | 5 |
Peers
Companies in Medical - Instruments & Supplies nearest West Pharmaceutical Services' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| WSTWest Pharmaceutical Services | $27.6B | 50.2× | 45.8× | 42.2× | 8.3× | +12% | 17.0% |
| RMDResMed | $36.5B | 24.2× | 37.3× | 20.8× | 6.5× | +10% | 26.9% |
| MDLNMedline | $44.8B | n/m | n/a | 23.2× | n/m | n/m | n/m |
| SOLVSolventum | $14.5B | 10.4× | 10.7× | n/m | 1.7× | −1% | 17.3% |
| BDXBecton, Dickinson and | $54.2B | 60.1× | 37.5× | 15.1× | 2.6× | +5% | 4.5% |
| PENPenumbra | $12.8B | 79.7× | 197× | n/m | 8.5× | +18% | 10.7% |
| COOCooper Companies | $11.6B | 20.9× | 40.2× | n/m | 2.7× | +5% | 13.5% |
| ALGNAlign Technology | $11B | 26.9× | 43.3× | n/m | 2.7× | +4% | 10.0% |
| GMEDGlobus Medical | $10.9B | 20.8× | 37.4× | n/m | 3.5× | +20% | 17.0% |
| PODDInsulet | $10.3B | 27.9× | 63.0× | n/m | 3.4× | +29% | 12.3% |
| MSAMSA Safety | $7B | 22.7× | 36.3× | n/m | 3.6× | +6% | 16.1% |
| Peer median | $12.2B | 24.2× | 37.5× | 20.8× | 3.4× | +6% | 13.5% |
Investors who own it
Investors we follow who held West Pharmaceutical Services at the end of Jun 30, 2026, from their 13F filings.
- Ron BaronBaron Capital0.1% of portfoliotrimmed
More on West Pharmaceutical Services
Each number over time
- PE ratio
- Forward PE
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Dividend yield
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .